Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to skepticism among some doctors.  Initially hopeful, Alzheimer’s experts anticipated challenges with Leqembi’s requirements, including frequent infusions and diagnostic tests, leading to slow adoption after FDA approval.  Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks, hampering widespread prescription. Read Next: European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer’s Drug Lecanemab. Reuters highlighted that seven interviewed doctors cited skepticism, while six highlighted “therapeutic nihilism” as a significant barrier to Leqembi adoption.  Dr. Reisa Sperling likened skepticism to past fatalistic attitudes toward cancer treatment. Eisai’s chief administrative ...